Abstract
Background
Enhanced recovery (ER) and fast-track protocols were initially implemented in the perioperative management of the surgical patient over 20 years ago. These standardized protocols are now broadly implemented across most surgical specialties for its many benefits. ER is well known for its positive effects on decreasing length of stay and complications. However, patient-centric outcomes for adequate pain control, functional recovery, costs, and overall patient experience are less considered.
How I Do It
A successful ER foundation stands on the pillars of several perioperative care principles: early feeding, early ambulation, goal-directed fluid therapy, and opiate-sparing analgesia. Moreover, it requires a multi-disciplinary team buy-in (including patient and family) that must also be thoughtfully executed. The following is a review of key elements within successful evidence-based ER protocols and relevant concepts to consider when starting a successful enhanced recovery program.
Similar content being viewed by others
References
Kehlet H, Wilmore DW. Fast-track surgery. Br J Surg. 2005;92(1):3–4.
Stottmeier S, Harling H, Wille-Jorgensen P, Balleby L, Kehlet H. Pathogenesis of morbidity after fast-track laparoscopic colonic cancer surgery. Colorectal Dis. 2011;13(5):500–505.
Song W, Wang K, Zhang RJ, Dai QX, Zou SB. The enhanced recovery after surgery (ERAS) program in liver surgery: a meta-analysis of randomized controlled trials. Springerplus. 2016;5:207.
Hughes MJ, McNally S, Wigmore SJ. Enhanced recovery following liver surgery: a systematic review and meta-analysis. HPB (Oxford). 2014;16(8):699–706.
Kim BJ, Tzeng CD, Cooper AB, Vauthey JN, Aloia TA. Borderline operability in hepatectomy patients is associated with higher rates of failure to rescue after severe complications. J Surg Oncol. 2017;115(3):337–343.
Karnofsky DA. Cancer Chemotherapeutic Agents. CA Cancer J Clin. 1964;14:67–72.
Cleeland CS, Mendoza TR, Wang XS, Chou C, Harle MT, Morrissey M, Engstrom MC. Assessing symptom distress in cancer patients: the M.D. Anderson Symptom Inventory. Cancer. 2000;89(7):1634–1646.
Carey EJ, Steidley DE, Aqel BA, Byrne TJ, Mekeel KL, Rakela J, Vargas HE, Douglas DD. Six-minute walk distance predicts mortality in liver transplant candidates. Liver Transpl. 2010;16(12):1373–1378.
Hofheinz M, Mibs M. The Prognostic Validity of the Timed Up and Go Test With a Dual Task for Predicting the Risk of Falls in the Elderly. Gerontol Geriatr Med. 2016;2:2333721416637798.
Nordin E, Lindelof N, Rosendahl E, Jensen J, Lundin-Olsson L. Prognostic validity of the Timed Up-and-Go test, a modified Get-Up-and-Go test, staff's global judgement and fall history in evaluating fall risk in residential care facilities. Age Ageing. 2008;37(4):442–448.
Takamoto T, Hashimoto T, Inoue K, Nagashima D, Maruyama Y, Mitsuka Y, Aramaki O, Makuuchi M. Applicability of enhanced recovery program for advanced liver surgery. World J Surg. 2014;38(10):2676–2682.
Granziera E, Guglieri I, Del Bianco P, Capovilla E, Dona B, Ciccarese AA, Kilmartin D, Manfredi V, De Salvo GL. A multidisciplinary approach to improve preoperative understanding and reduce anxiety: a randomised study. Eur J Anaesthesiol. 2013;30(12):734–742.
Djaladat H, Bruins HM, Miranda G, Cai J, Skinner EC, Daneshmand S. The association of preoperative serum albumin level and American Society of Anesthesiologists (ASA) score on early complications and survival of patients undergoing radical cystectomy for urothelial bladder cancer. BJU Int. 2014;113(6):887–893.
Lucas DJ, Haider A, Haut E, Dodson R, Wolfgang CL, Ahuja N, Sweeney J, Pawlik TM. Assessing readmission after general, vascular, and thoracic surgery using ACS-NSQIP. Ann Surg. 2013;258(3):430–439.
Wagner D, DeMarco MM, Amini N, Buttner S, Segev D, Gani F, Pawlik TM. Role of frailty and sarcopenia in predicting outcomes among patients undergoing gastrointestinal surgery. World J Gastrointest Surg. 2016;8(1):27–40.
Lin MY, Liu WY, Tolan AM, Aboulian A, Petrie BA, Stabile BE. Preoperative serum albumin but not prealbumin is an excellent predictor of postoperative complications and mortality in patients with gastrointestinal cancer. Am Surg. 2011;77(10):1286–1289.
Brady M, Kinn S, Stuart P. Preoperative fasting for adults to prevent perioperative complications. Cochrane Database Syst Rev. 2003(4):CD004423.
Zmora O, Mahajna A, Bar-Zakai B, Rosin D, Hershko D, Shabtai M, Krausz MM, Ayalon A. Colon and rectal surgery without mechanical bowel preparation: a randomized prospective trial. Ann Surg. 2003;237(3):363–367.
Nygren J, Thorell A, Ljungqvist O. Preoperative oral carbohydrate nutrition: an update. Curr Opin Clin Nutr Metab Care. 2001;4(4):255–259.
Hausel J, Nygren J, Lagerkranser M, Hellstrom PM, Hammarqvist F, Almstrom C, Lindh A, Thorell A, Ljungqvist O. A carbohydrate-rich drink reduces preoperative discomfort in elective surgery patients. Anesth Analg. 2001;93(5):1344–1350.
Svanfeldt M, Thorell A, Hausel J, Soop M, Rooyackers O, Nygren J, Ljungqvist O. Randomized clinical trial of the effect of preoperative oral carbohydrate treatment on postoperative whole-body protein and glucose kinetics. Br J Surg. 2007;94(11):1342–1350.
Bratzler DW, Houck PM, Surgical Infection Prevention Guideline Writers W. Antimicrobial prophylaxis for surgery: an advisory statement from the National Surgical Infection Prevention Project. Am J Surg. 2005;189(4):395–404.
Ljungqvist O, Scott M, Fearon KC. Enhanced Recovery After Surgery: A Review. JAMA Surg. 2017;152(3):292–298.
Darouiche RO, Wall MJ, Jr., Itani KM, Otterson MF, Webb AL, Carrick MM, Miller HJ, Awad SS, Crosby CT, Mosier MC, Alsharif A, Berger DH. Chlorhexidine-Alcohol versus Povidone-Iodine for Surgical-Site Antisepsis. N Engl J Med. 2010;362(1):18–26.
Lennon FE, Moss J, Singleton PA. The mu-opioid receptor in cancer progression: is there a direct effect? Anesthesiology. 2012;116:940–945.
Lennon FE, Mirzapoiazova T, Mambetsariev B, Poroyko VA, Salgia R, Moss J, Singleton PA. The Mu opioid receptor promotes opioid and growth factor-induced proliferation, migration and Epithelial Mesenchymal Transition (EMT) in human lung cancer. PLoS One. 2014;9(3):e91577.
Mathew B, Lennon FE, Siegler J, Mirzapoiazova T, Mambetsariev N, Sammani S, Gerhold LM, LaRiviere PJ, Chen CT, Garcia JG, Salgia R, Moss J, Singleton PA. The novel role of the mu opioid receptor in lung cancer progression: a laboratory investigation. Anesth Analg. 2011;112(3):558–567.
Bortsov AV, Millikan RC, Belfer I, Boortz-Marx RL, Arora H, McLean SA. mu-Opioid receptor gene A118G polymorphism predicts survival in patients with breast cancer. Anesthesiology. 2012;116(4):896–902.
Wang S, Li Y, Liu XD, Zhao CX, Yang KQ. Polymorphism of A118G in mu-opioid receptor gene is associated with risk of esophageal squamous cell carcinoma in a Chinese population. Int J Clin Oncol. 2013;18(4):666–669.
Singleton PA, Lingen MW, Fekete MJ, Garcia JG, Moss J. Methylnaltrexone inhibits opiate and VEGF-induced angiogenesis: role of receptor transactivation. Microvasc Res. 2006;72(1–2):3–11.
Denlinger CE, Ikonomidis JS, Reed CE, Spinale FG. Epithelial to mesenchymal transition: the doorway to metastasis in human lung cancers. J Thorac Cardiovasc Surg. 2010;140(3):505–513.
Iwatsuki M, Mimori K, Yokobori T, Ishi H, Beppu T, Nakamori S, Baba H, Mori M. Epithelial-mesenchymal transition in cancer development and its clinical significance. Cancer Sci. 2010;101(2):293–299.
Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest. 2009;119(6):1420–1428.
Voulgari A, Pintzas A. Epithelial-mesenchymal transition in cancer metastasis: mechanisms, markers and strategies to overcome drug resistance in the clinic. Biochim Biophys Acta. 2009;1796(2):75–90.
Singh B, Lucci A. Role of cyclooxygenase-2 in breast cancer. J Surg Res. 2002;108(1):173–179.
Singh-Ranger G, Mokbel K. The role of cyclooxygenase-2 (COX-2) in breast cancer, and implications of COX-2 inhibition. Eur J Surg Oncol. 2002;28(7):729–737.
Morre DJ, Morre DM. tNOX, an alternative target to COX-2 to explain the anticancer activities of non-steroidal anti-inflammatory drugs (NSAIDS). Mol Cell Biochem. 2006;283(1–2):159–167.
Forget P, Vandenhende J, Berliere M, Machiels JP, Nussbaum B, Legrand C, De Kock M. Do intraoperative analgesics influence breast cancer recurrence after mastectomy? A retrospective analysis. Anesth Analg. 2010;110(6):1630–1635.
Correa-Gallego C, Tan KS, Arslan-Carlon V, Gonen M, Denis SC, Langdon-Embry L, Grant F, Kingham TP, DeMatteo RP, Allen PJ, D'Angelica MI, Jarnagin WR, Fischer M. Goal-Directed Fluid Therapy Using Stroke Volume Variation for Resuscitation after Low Central Venous Pressure-Assisted Liver Resection: A Randomized Clinical Trial. J Am Coll Surg. 2015;221(2):591–601.
Berri RN, Sahai SK, Durand JB, Lin HY, Folloder J, Rozner MA, Gottumukkala V, Katz MH, Lee JE, Fleming JB. Serum brain naturietic peptide measurements reflect fluid balance after pancreatectomy. J Am Coll Surg. 2012;214(5):778–787.
Friese RS, Dineen S, Jennings A, Pruitt J, McBride D, Shafi S, Frankel H, Gentilello LM. Serum B-type natriuretic peptide: a marker of fluid resuscitation after injury? J Trauma. 2007;62(6):1346–1350; discussion 1350-1341.
Bonow RO. New insights into the cardiac natriuretic peptides. Circulation. 1996;93(11):1946–1950.
Aloia TA, Geerts WH, Clary BM, Day RW, Hemming AW, D'Albuquerque LC, Vollmer CM, Jr., Vauthey JN, Toogood GJ. Venous Thromboembolism Prophylaxis in Liver Surgery. J Gastrointest Surg. 2016;20(1):221–229.
Bergqvist D, Agnelli G, Cohen AT, Eldor A, Nilsson PE, Le Moigne-Amrani A, Dietrich-Neto F, Investigators EI. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med. 2002;346(13):975–980.
Gould MK, Garcia DA, Wren SM, Karanicolas PJ, Arcelus JI, Heit JA, Samama CM, American College of Chest P. Prevention of VTE in nonorthopedic surgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e227S–277S.
Tzeng CW, Curley SA, Vauthey JN, Aloia TA. Distinct predictors of pre- versus post-discharge venous thromboembolism after hepatectomy: analysis of 7621 NSQIP patients. HPB (Oxford). 2013;15(10):773–780.
Bellini G, Teng A, Kotecha N, Sutton E, Yang CK, Passeri M, Lee DY, Rose K. The identification of risk factors for venous thromboembolism in gastrointestinal oncologic surgery. J Surg Res. 2016;205(2):279–285.
Ho KM, Tan JA. Stratified meta-analysis of intermittent pneumatic compression of the lower limbs to prevent venous thromboembolism in hospitalized patients. Circulation. 2013;128(9):1003–1020.
Day RW, Cleeland CS, Wang XS, Fielder S, Calhoun J, Conrad C, Vauthey JN, Gottumukkala V, Aloia TA. Patient-Reported Outcomes Accurately Measure the Value of an Enhanced Recovery Program in Liver Surgery. J Am Coll Surg. 2015;221(6):1023–1030 e1021-1022.
Aloia TA, Zimmitti G, Conrad C, Gottumukalla V, Kopetz S, Vauthey JN. Return to intended oncologic treatment (RIOT): a novel metric for evaluating the quality of oncosurgical therapy for malignancy. J Surg Oncol. 2014;110(2):107–114.
Bodenheimer T, Sinsky C. From triple to quadruple aim: care of the patient requires care of the provider. Ann Fam Med. 2014;12(6):573–576.
Funding
Dr. Bradford Kim is supported by the National Institutes of Health grant T32CA009599.
Author information
Authors and Affiliations
Corresponding author
Additional information
Disclosure Information
Authors: Thomas A. Aloia, M.D. has nothing to disclose. Bradford J. Kim, M.D., M.H.S. has nothing to disclose. Editors-in-Chief: Richard A. Hodin, M.D., Timothy M. Pawlik, M.D., MPH, PhD has nothing to disclose. CME Overseers: Arbiter: Timothy M. Pawlik, M.D., MPH, PhD has nothing to disclose; Vice-Arbiter: Melanie Morris, M.D. has nothing to disclose; Question Reviewers: Michael Anthony Edwards, M.D. has nothing to disclose; F. Andrew Morfesis, M.D. has nothing to disclose.
Learning Objectives
1. Define enhanced recovery in surgery
2. Understand all goals of enhanced recovery
3. Discuss several key components of enhanced recovery
4. Understand the team-based approach and buy in required to successfully execute enhanced recovery
Questions:
1. What are the best parameters to measure effective goal-directed fluid therapy (GDFT)?
a. Heart rate
b. Urine output
c. Stroke volume and corrected flow time
d. Blood pressure
2. Which of the following statements are true about narcotics in cancer patients?
a. Patients with tumors expressing polymorphism of the mu-opioid receptor (MOR) will have better survival
b. Opioids can activate vascular endothelial growth factors (VEGF)
c. Opioids should be administered as much as possible to promote enhanced recovery
d. NSAIDs should be avoided in the cancer patient because of their effects on recurrence
3. When compared to traditional pathways, outcomes of enhanced recovery include which of the following?
a. Increased length of stay but decreased costs
b. Improved patient-reported functional outcomes
c. Increased use of narcotics
d. Similar rates of morbidity
4. Select the most critical component of enhanced recovery
a. Bowel regimen
b. Aggressive fluid resuscitation
c. Copious narcotic use to control pain
d. Patient education and engagement
e. Early feeding
5. How long antibiotics should be continued in the perioperative period for antimicrobial prophylaxis?
a. POD 1
b. POD 2
c. POD 5 (if still in the hospital)
d. Until hospital discharge
6. How early can intravenous fluid be discontinued?
a. After 600 mL of clear liquids are tolerated
b. After full liquid diet is tolerated
c. After regular diet is tolerated
d. After passing of flatus
7. For major HPB surgery, when should anticoagulant thromboprophylaxis be started?
a. POD 0/1
b. POD 2/3
c. When INR is normal
d. Never
8. When should the urinary catheter be removed after major gastrointestinal surgery?
a. It should never be placed for gastrointestinal surgery
b. Before extubation
c. After ambulation
d. After tolerating regular diet
CME questions for this article available to SSAT members at http://ssat.com/jogscme/
Rights and permissions
About this article
Cite this article
Kim, B.J., Aloia, T.A. What Is “Enhanced Recovery,” and How Can I Do It?. J Gastrointest Surg 22, 164–171 (2018). https://doi.org/10.1007/s11605-017-3605-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11605-017-3605-9